For research use only. Not for therapeutic Use.
CC-223（Cat No.:I000885）is a potent and selective dual inhibitor of mTORC1 and mTORC2, making it a valuable tool for cancer research. By targeting the mechanistic target of rapamycin (mTOR) pathways, CC-223 disrupts cellular growth, proliferation, and survival mechanisms in various cancers. Its inhibition of both mTOR complexes enhances its therapeutic potential, especially in tumors resistant to traditional mTOR inhibitors. This compound is widely used in preclinical studies to explore its effects on tumor growth, metabolism, and response to treatments, contributing to the development of novel cancer therapies.
| Catalog Number | I000885 |
| CAS Number | 1228013-30-6 |
| Synonyms | 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((1r,4r)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one |
| Molecular Formula | C21H27N5O3 |
| Purity | ≥95% |
| Target | mTOR; Apoptosis |
| Solubility | DMSO: ≥ 27 mg/mL |
| Storage | Store at -20°C |
| IC50 | 16 nM |
| IUPAC Name | 3-[6-(2-hydroxypropan-2-yl)pyridin-3-yl]-5-(4-methoxycyclohexyl)-7,8-dihydropyrazino[2,3-b]pyrazin-6-one |
| InChI | InChI=1S/C21H27N5O3/c1-21(2,28)17-9-4-13(10-22-17)16-11-23-19-20(25-16)26(18(27)12-24-19)14-5-7-15(29-3)8-6-14/h4,9-11,14-15,28H,5-8,12H2,1-3H3,(H,23,24) |
| InChIKey | UFKLYTOEMRFKAD-UHFFFAOYSA-N |
| SMILES | CC(C)(C1=NC=C(C=C1)C2=CN=C3C(=N2)N(C(=O)CN3)C4CCC(CC4)OC)O |
| Reference | </br>1:CC-223 blocks mTORC1/C2 activation and inhibits human hepatocellular carcinoma cells in vitro and in vivo. Xie Z, Wang J, Liu M, Chen D, Qiu C, Sun K.PLoS One. 2017 Mar 23;12(3):e0173252. doi: 10.1371/journal.pone.0173252. eCollection 2017. PMID: 28334043 Free PMC Article</br>2:A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma. Bendell JC, Kelley RK, Shih KC, Grabowsky JA, Bergsland E, Jones S, Martin T, Infante JR, Mischel PS, Matsutani T, Xu S, Wong L, Liu Y, Wu X, Mortensen DS, Chopra R, Hege K, Munster PN.Cancer. 2015 Oct 1;121(19):3481-90. doi: 10.1002/cncr.29422. Epub 2015 Jul 15. PMID: 26177599 Free PMC Article</br>3:Discovery of mammalian target of rapamycin (mTOR) kinase inhibitor CC-223. Mortensen DS, Perrin-Ninkovic SM, Shevlin G, Zhao J, Packard G, Bahmanyar S, Correa M, Elsner J, Harris R, Lee BG, Papa P, Parnes JS, Riggs JR, Sapienza J, Tehrani L, Whitefield B, Apuy J, Bisonette RR, Gamez JC, Hickman M, Khambatta G, Leisten J, Peng SX, Richardson SJ, Cathers BE, Canan SS, Moghaddam MF, Raymon HK, Worland P, Narla RK, Fultz KE, Sankar S.J Med Chem. 2015 Jul 9;58(13):5323-33. doi: 10.1021/acs.jmedchem.5b00626. Epub 2015 Jun 26. PMID: 26083478 </br>4:CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization. Mortensen DS, Fultz KE, Xu S, Xu W, Packard G, Khambatta G, Gamez JC, Leisten J, Zhao J, Apuy J, Ghoreishi K, Hickman M, Narla RK, Bissonette R, Richardson S, Peng SX, Perrin-Ninkovic S, Tran T, Shi T, Yang WQ, Tong Z, Cathers BE, Moghaddam MF, Canan SS, Worland P, Sankar S, Raymon HK.Mol Cancer Ther. 2015 Jun;14(6):1295-305. doi: 10.1158/1535-7163.MCT-14-1052. Epub 2015 Apr 8. PMID: 25855786 Free Article |
